Literature DB >> 24500310

Hemiasterlin analogues incorporating an aromatic, and heterocyclic type C-terminus: design, synthesis and biological evaluation.

Giordano Lesma1, Alessandro Sacchetti, Rouli Bai, Giuseppe Basso, Roberta Bortolozzi, Ernest Hamel, Alessandra Silvani, Nadia Vaiana, Giampietro Viola.   

Abstract

A representative series of structural analogs of the antimitotic tripeptides hemiasterlins have been designed and synthesized, as potential inhibitors of tubulin polymerization. Relying also on a computational approach, we aimed to explore unknown extensive changes at the C-fragment, by incorporating the conformationally required double bond into five- and six-membered rings. Key steps of the synthetic strategy are a dynamic resolution affording the A-fragment in 97 % ee and the preparation of six new cyclic C fragments, all potentially able to interact with tubulin by means of H bonds. Unexpectedly, biological evaluation of these analogs did not provide evidences neither for cytotoxic effect nor for inhibition of tubulin polymerization.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24500310      PMCID: PMC4081462          DOI: 10.1007/s11030-014-9507-9

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  30 in total

Review 1.  Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin.

Authors:  Ernest Hamel
Journal:  Cell Biochem Biophys       Date:  2003       Impact factor: 2.194

2.  Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues.

Authors:  James A Nieman; John E Coleman; Debra J Wallace; Edward Piers; Lynette Y Lim; Michel Roberge; Raymond J Andersen
Journal:  J Nat Prod       Date:  2003-02       Impact factor: 4.050

3.  Synthesis and biological activity of analogues of the antimicrotubule agent N,beta,beta-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]- N(1),3-dimethyl-L-valinamide (HTI-286).

Authors:  Arie Zask; Gary Birnberg; Katherine Cheung; Joshua Kaplan; Chuan Niu; Emily Norton; Ronald Suayan; Ayako Yamashita; Derek Cole; Zhilian Tang; Girija Krishnamurthy; Robert Williamson; Gulnaz Khafizova; Sylvia Musto; Richard Hernandez; Tami Annable; Xiaoran Yang; Carolyn Discafani; Carl Beyer; Lee M Greenberger; Frank Loganzo; Semiramis Ayral-Kaloustian
Journal:  J Med Chem       Date:  2004-09-09       Impact factor: 7.446

4.  Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment.

Authors:  Ayako Yamashita; Emily B Norton; Joshua A Kaplan; Chuan Niu; Frank Loganzo; Richard Hernandez; Carl F Beyer; Tami Annable; Sylvia Musto; Carolyn Discafani; Arie Zask; Semiramis Ayral-Kaloustian
Journal:  Bioorg Med Chem Lett       Date:  2004-11-01       Impact factor: 2.823

5.  Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.

Authors:  R Bai; N A Durso; D L Sackett; E Hamel
Journal:  Biochemistry       Date:  1999-10-26       Impact factor: 3.162

6.  Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor.

Authors:  Lih-Ching Hsu; David E Durrant; Ching-Chun Huang; Nai-Wen Chi; Riccardo Baruchello; Riccardo Rondanin; Cinzia Rullo; Paolo Marchetti; Giuseppina Grisolia; Daniele Simoni; Ray M Lee
Journal:  Invest New Drugs       Date:  2011-06-08       Impact factor: 3.850

7.  HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

Authors:  Frank Loganzo; Carolyn M Discafani; Tami Annable; Carl Beyer; Sylvia Musto; Malathi Hari; Xingzhi Tan; Carolyn Hardy; Richard Hernandez; Michelle Baxter; Thiruvikraman Singanallore; Gulnaz Khafizova; Marianne S Poruchynsky; Tito Fojo; James A Nieman; Semiramis Ayral-Kaloustian; Arie Zask; Raymond J Andersen; Lee M Greenberger
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

8.  Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.

Authors:  Frank Loganzo; Malathi Hari; Tami Annable; Xingzhi Tan; Daniel B Morilla; Sylvia Musto; Arie Zask; Joshua Kaplan; Albert A Minnick; Michael K May; Semiramis Ayral-Kaloustian; Marianne S Poruchynsky; Tito Fojo; Lee M Greenberger
Journal:  Mol Cancer Ther       Date:  2004-10       Impact factor: 6.261

9.  D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors.

Authors:  Arie Zask; Gary Birnberg; Katherine Cheung; Joshua Kaplan; Chuan Niu; Emily Norton; Ayako Yamashita; Carl Beyer; Girija Krishnamurthy; Lee M Greenberger; Frank Loganzo; Semiramis Ayral-Kaloustian
Journal:  Bioorg Med Chem Lett       Date:  2004-08-16       Impact factor: 2.823

Review 10.  The clinical development of new mitotic inhibitors that stabilize the microtubule.

Authors:  Sridhar Mani; Manuel Macapinlac; Sanjay Goel; Dominik Verdier-Pinard; Tito Fojo; Mace Rothenberg; Dimitrios Colevas
Journal:  Anticancer Drugs       Date:  2004-07       Impact factor: 2.248

View more
  2 in total

1.  Complementary isonitrile-based multicomponent reactions for the synthesis of diversified cytotoxic hemiasterlin analogues.

Authors:  Giordano Lesma; Ivan Bassanini; Roberta Bortolozzi; Chiara Colletto; Ruoli Bai; Ernest Hamel; Fiorella Meneghetti; Giulia Rainoldi; Mattia Stucchi; Alessandro Sacchetti; Alessandra Silvani; Giampietro Viola
Journal:  Org Biomol Chem       Date:  2015-10-15       Impact factor: 3.876

Review 2.  Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.

Authors:  Hao Chen; Zongtao Lin; Kinsie E Arnst; Duane D Miller; Wei Li
Journal:  Molecules       Date:  2017-08-01       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.